An observational study in Indeterminate Thyroid Nodules, sponsored by University of Cagliari. Recruiting at 1 site in Italy. Per ClinicalTrials.gov, last updated 2023-05-09.
Sponsored by University of Cagliari · Observational
Among 58 studies in Thyroid Neoplasms with a site in Italy — 18 open to participants now, 22 under way, 1 of them phase 3. Thyroid Neoplasms · Italy.
Among the 58 studies in Thyroid Neoplasms with a site in Italy, this one is the 2nd largest by planned enrollment of the 27 observational ones that give a count, is one of 7 that started in 2023, is one of 27 observational ones, reaches primary completion later than 3 of the 21 other live ones, and was the 46th registered.
785 studies on the registry are indexed under Thyroid Neoplasms; 204 are open to participants now.
Browse Thyroid Neoplasms studies →18 of the 58 studies in Thyroid Neoplasms with a site in Italy are open now. Recruiting first, the newest first:
Università Cattolica di Milano · Sites in Italy
Ages 18–100
IRCCS Azienda Ospedaliero-Universitaria di Bologna · Sites in Italy
Ages 10–43
Azienda Ospedaliera di Padova · Sites in Italy
Ages 0–18
Istituti Clinici Scientifici Maugeri SpA · Sites in Italy
Ages 18+
University of Modena and Reggio Emilia · Sites in Italy
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 152 Thyroid Neoplasms studies recruiting now, 96 (63%) set no upper age limit and 27 (18%) stop at 75 or younger; 37 take children under 18; 13 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
58 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 17 · Phase 3 8 · Phase 4 2
First in 2004; this study’s year is marked. 7 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 10,000 is above the median of 178 across 241 observational studies indexed under Thyroid Neoplasms.
Median enrollment 200 across the 31 interventional studies, 144 across the 27 observational. Of the 31 that completed or were terminated, 15 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 58 have an industry lead sponsor. The 10 most frequent:
University of Cagliari is the lead sponsor of 85 studies on the registry; 17 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 1 (17%) have results posted.
University of Cagliari has 4 studies filed under Thyroid Neoplasms — fewer than ten, so there is no comparison to draw.
3 of the studies in Thyroid Neoplasms with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05852223Istituti Clinici Scientifici Maugeri SpAPembrolizumab in High-risk Thyroid Cancer | 2026-11 |
| NCT06863805IRCCS Azienda Ospedaliero-Universitaria di BolognaEvaluation of the Clinical Utility of Circulating Biomarkers in Advanced Thyroid Carcinomas | 2026-12-31 |
| NCT05428371University of CagliariAssessment the Cancer Risk of Indeterminate Thyroid Nodules Through Integration of Clinical, Ultrasonographic and Multiomic Features | 2027-05-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 58 studies in Thyroid Neoplasms with a site in Italy, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Thyroid carcinoma (TC) is the most common endocrine malignancy, affecting 0.2-1.5% of individuals worldwide. The rising incidence rate of TC is mostly related to the expanding use of high-quality imaging techniques, with an increase in the detection of thyroid nodules. Fine needle aspiration cytology (FNAC) is the most accurate, rapid, safe, and cost-effective test for the evaluation of thyroid nodules, with high specificity and sensitivity. Nevertheless, FNAC is particularly unreliable in differentiating between benign and malignant nodules that fall under the category of indeterminate thyroid nodules (class III and class IV according to Bethesda Classification[2]). In fact, in these cases, the expected malignancy rates are 5-15% and 15-30%, respectively. Thus, most patients with indeterminate thyroid nodules undergo an operation that is indeed unnecessary, while representing a risk for surgical complications and a cost for health-care systems.
We aim to evaluate different approaches to indeterminate nodules across different countries in the world.
We aim to investigate different approaches to indeterminate thyroid nodules across different countries worldwide
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients that underwent thyroidectomy for indeterminate thyroid nodules in the SEAR
Procedure: Thyroidectomy
Patients that underwent thyroidectomy for indeterminate thyroid nodules in the AMR
Procedure: Thyroidectomy
Patients that underwent thyroidectomy for indeterminate thyroid nodules in the EMR
Procedure: Thyroidectomy
Patients that underwent thyroidectomy for indeterminate thyroid nodules in the EUR
Procedure: Thyroidectomy
Patients that underwent thyroidectomy for indeterminate thyroid nodules in the WPR
Procedure: Thyroidectomy
Total thyroidectomy or lobectomy
Rate of malignancy
Number of cancers over the total patients submitted to thyroidectomy for indeterminate thyroid nodules
Time frame: 36 months
Surgical approach to indeterminate thyroid nodules
Number of lobectomies over the total patients submitted to thyroidectomy for indeterminate thyroid nodules
Time frame: 36 months
Plan to share: Undecided
No publications or documents are linked to this record.
Started Apr 2023 (actual). Primary completion is estimated for Jul 2023, 3 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Cagliari